HHS downplays importation savings

HHS reported to Congress that unrestricted importation of drugs into the U.S. would produce marginal savings, pose major safety risks, and reduce incentives for the development of new therapies. The report, which was drafted by the

Read the full 367 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE